Be sure to check our sister interview main ratings news website

Poolbeg Pharma A Strategic Vision, Pioneering the Future of Innovative Medicine

A Poolbeg Pharma Plc (LON:POLB) Investor Presentation for January 2024 presented by CEO Jeremy Skillington and outlines the company’s strategic shift towards generating sustainable revenue and achieving profitability.

It highlights Poolbeg’s focus on the development and commercialisation of innovative medicines for unmet medical needs. Key components include the leveraging of a proven leadership team with a successful track record in the pharmaceutical industry, a business model centred around revenue generation from commercial-stage products, and the development of high-value programs for partnering, including their lead candidate POLB 001 for cancer immunotherapy-induced CRS and severe influenza. The presentation also discusses the company’s strong financial position and ongoing strategic collaborations.

Read in Full
Click to view all articles for the EPIC:
Or click to view the full company profile:
Facebook
X
LinkedIn

More articles like this

AI-powered drug discovery is changing the future of medicine

31st January 2025

The pharmaceutical industry is being revolutionised by AI, transforming drug discovery with faster research and innovative treatments. Poolbeg Pharma plc (LON:POLB) is a clinical stage infectious disease pharmaceutical company, leveraging a novel clinical model for faster product development.

The Medicine of Tomorrow

23rd January 2025

Discover how groundbreaking research is revolutionising disease treatment at Monash Institute of Pharmaceutical Sciences. AI, biology, and data converge for life-changing advancements.

Hookipa Pharma advancing bold acquisition plans with Poolbeg Pharma

9th January 2025

US-based biopharmaceutical innovator Hookipa Pharma is advancing non-binding discussions to acquire London-based Poolbeg Pharma in an all-share deal. This transformative proposal could reshape the clinical-stage biopharmaceutical landscape, creating a Nasdaq-listed powerhouse focused on next-generation immunotherapies for

Poolbeg receives US patent for Immunomodulator development

21st November 2024

Poolbeg Pharma plc, a clinical-stage biopharmaceutical company, has announced that the US Patent Office will grant its US Immunomodulator I patent application. The patent covers POLB 001, a selective p38 MAP kinase inhibitor, and other similar

Poolbeg Pharma awarded POLB 001 patent in United States

20th November 2024

Poolbeg Pharma plc (LON:POLB), a clinical-stage biopharmaceutical company focused on the development and commercialisation of innovative medicines targeting diseases with a high unmet medical need, has announced that the US Patent Office has notified the Company of its official decision

AI in Pharmaceuticals

14th November 2024

Artificial intelligence in the pharmaceutical industry has become central to modern drug discovery and development. Recognising both its potential and its risks, the FDA has initiated efforts to regulate AI’s role in the sector, balancing innovation

© 2024 – DirectorsTalk. All rights reserved. Reproduction in whole or in part, in any form or medium without express written permission is prohibited.